MCID: PNC044
MIFTS: 61

Pancreatitis

Categories: Bone diseases, Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Pancreatitis

MalaCards integrated aliases for Pancreatitis:

Name: Pancreatitis 12 24 29 54 6 42 15 39 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4989
MeSH 43 D010195
NCIt 49 C3306
SNOMED-CT 67 75694006
ICD10 32 K85.9
UMLS 71 C0030305

Summaries for Pancreatitis

MedlinePlus : 42 The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Pancreatitis is related to pancreatitis, hereditary and tropical calcific pancreatitis, and has symptoms including nausea and vomiting, abdominal pain and constipation. An important gene associated with Pancreatitis is TMEM67 (Transmembrane Protein 67), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Pancreatic secretion. The drugs Somatostatin and Cefoperazone have been mentioned in the context of this disorder. Affiliated tissues include pancreas, testes and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Pancreatitis is a condition characterized by inflammation of the pancreas. The pancreas is a large organ... more...

GeneReviews: NBK190101

Related Diseases for Pancreatitis

Diseases in the Pancreatitis family:

Pancreatitis, Hereditary Autoimmune Pancreatitis
Acute Pancreatitis Prss1-Related Hereditary Pancreatitis
Autoimmune Pancreatitis Type 2 Autoimmune Pancreatitis Type 1

Diseases related to Pancreatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2451)
# Related Disease Score Top Affiliating Genes
1 pancreatitis, hereditary 35.0 SPINK1 PRSS2 PRSS1 CTRC CPA1 CFTR
2 tropical calcific pancreatitis 34.9 SPINK1 REG1A PRSS2 PRSS1 CTRC
3 pancreatic agenesis 1 34.8 SPINK1 SCT PNLIP CFTR
4 pancreatic cancer 34.7 SST SPINK1 SCT REG3A REG1A PRSS1
5 pancreatic cholera 34.5 SST SCT
6 exocrine pancreatic insufficiency 34.4 SPINK1 SCT PRSS1 PNLIP CFTR CCK
7 pancreatic steatorrhea 34.4 SCT PRSS1 PNLIP CCK
8 pancreatic gastrinoma 34.2 SST SCT
9 glucagonoma 34.1 SST SCT
10 prss1-related hereditary pancreatitis 34.0 SPINK1 PRSS2 PRSS1 CTRC CFTR
11 acute pancreatitis 33.8 VMP1 SST SPINK1 SCT REG3A PRSS1
12 alcoholic pancreatitis 33.8 SPINK1 SCT REG3A PRSS1 LPL CPB1
13 pancreas, annular 33.3 SPINK1 SCT PRSS1
14 familial lipoprotein lipase deficiency 33.2 PNLIP LPL APOC2
15 enterokinase deficiency 33.1 SCT CCK
16 hyperlipoproteinemia, type i 32.9 PNLIP LPL APOC2
17 neuroendocrine tumor 32.7 SST SCT CCK
18 cholecystolithiasis 32.7 SST CCK
19 apolipoprotein c-ii deficiency 32.7 LPL APOC2
20 biliary dyskinesia 32.6 SST SPINK1 SCT REG3A PRSS1 CFTR
21 bile acid malabsorption, primary 32.6 SST SCT PNLIP CFTR CCK
22 multiple endocrine neoplasia, type i 32.6 SST SCT CASR
23 maturity-onset diabetes of the young 32.5 SST REG1A LPL APOC2
24 lipase deficiency, combined 32.3 PNLIP LPL
25 diabetes mellitus, noninsulin-dependent 32.1 SST SCT REG1A PNLIP PLA2G2A LPL
26 duodenal obstruction 31.8 SPINK1 PRSS1
27 duodenal ulcer 31.6 SST SCT CCK
28 ileus 31.6 SST CFTR CCK
29 diarrhea 31.6 SST SCT CFTR CCK
30 gastrinoma 31.5 SST SCT CASR
31 endocrine pancreas disease 31.2 SST SCT
32 diabetes mellitus 31.2 SST SPINK1 SCT REG1A PNLIP LPL
33 gallbladder disease 31.0 SST CFTR CCK
34 bile reflux 30.9 SCT CCK
35 duodenogastric reflux 30.7 SST SCT CCK
36 dumping syndrome 30.6 SST SCT CCK
37 duodenal gastrinoma 30.5 SST SCT
38 familial hyperlipidemia 30.4 PNLIP LPL APOC2
39 linitis plastica 30.2 PRSS2 PRSS1
40 cystic kidney disease 30.0 TMEM67 SST SCT CFTR
41 polycystic kidney disease 4 with or without polycystic liver disease 29.8 TMEM67 SST CFTR
42 polycystic liver disease 29.7 TMEM67 SST SCT CFTR
43 hyperlipoproteinemia, type v 29.6 LPL APOC2
44 pancreatic lipase deficiency 12.7
45 pancreatic ductal adenocarcinoma 12.7
46 autoimmune pancreatitis 12.7
47 pancreatic ductal carcinoma 12.6
48 melanoma-pancreatic cancer syndrome 12.6
49 neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 12.6
50 pancreatic adenocarcinoma 12.6

Graphical network of the top 20 diseases related to Pancreatitis:



Diseases related to Pancreatitis

Symptoms & Phenotypes for Pancreatitis

UMLS symptoms related to Pancreatitis:


nausea and vomiting, abdominal pain, constipation, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Pancreatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.23 SST
2 Decreased viability GR00249-S 9.23 CPB1 PRSS1
3 Decreased viability GR00381-A-1 9.23 SCT
4 Decreased viability GR00386-A-1 9.23 CCK LPL
5 Decreased viability GR00402-S-2 9.23 CTRC SCT

MGI Mouse Phenotypes related to Pancreatitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 CASR CFTR CTRC PNLIP SPINK1 SST
2 homeostasis/metabolism MP:0005376 9.44 APOC2 CASR CCK CFTR LPL PNLIP

Drugs & Therapeutics for Pancreatitis

Drugs for Pancreatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 495)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
2
Cefoperazone Approved, Investigational Phase 4 62893-19-0 44185
3
Metronidazole Approved Phase 4 443-48-1 4173
4 Pinaverium Approved Phase 4 59995-65-2
5
Lorazepam Approved Phase 4 846-49-1 3958
6
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
7
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 441130 64778
10
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
11
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
12
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
13
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
14
Secretin Approved Phase 4 108153-74-8
15
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
16
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
17
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
18
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
19
Morphine Approved, Investigational Phase 4 57-27-2 5288826
20
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
21
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
22
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
23
Liraglutide Approved Phase 4 204656-20-2 44147092
24
Glucagon Approved Phase 4 16941-32-5
25
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
26
Thrombin Approved, Investigational Phase 4
27
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
28
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
29
Meperidine Approved Phase 4 57-42-1 4058
30
Etomidate Approved Phase 4 33125-97-2 36339 667484
31
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
32
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
33
Lopinavir Approved Phase 4 192725-17-0 92727
34
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
35
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
36 Hydrotalcite Approved, Experimental, Investigational Phase 4 12304-65-3
37
Sucralfate Approved Phase 4 54182-58-0
38
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
39
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
40
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
41
Polyestradiol phosphate Approved Phase 4 28014-46-2
42
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
43
Glycerol Approved, Investigational Phase 4 56-81-5 753
44
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 151165
45
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
46
Protein C Approved Phase 4
47
Etanercept Approved, Investigational Phase 4 185243-69-0
48
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
49
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
50
Ofloxacin Approved Phase 4 82419-36-1 4583

Interventional clinical trials:

(show top 50) (show all 821)
# Name Status NCT ID Phase Drugs
1 Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis Unknown status NCT02839356 Phase 4 epinephrine;normal saline
2 Comparative Study About the Impact of Two Oil Emulsions, One of Them Formulated With MCT, LCT, Olive Oil and Omega 3 Fatty Acids Versus Another One Formulated With MCT and LCT, Administered Intravenously on Severe Acute Pancreatitis Clinical Evolution Unknown status NCT01376817 Phase 4 Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids;Fat emulsion with MCT and LCT
3 Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Unknown status NCT02691598 Phase 4 Infusion
4 Oral Resveratrol Before ERCP Redused Overall Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Multi-center, Single-blinded, Randomized Controlled Trial Unknown status NCT02947932 Phase 4 Resveratrol;Indomethacin
5 Effect Observation Study of COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis Unknown status NCT02964403 Phase 4 Cox-2;Indomethacin
6 Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis Unknown status NCT01992198 Phase 4 cefoperazone + metronidazole;Somatostatin;Meropenem
7 Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal: A Prospective Study. Unknown status NCT03082469 Phase 4
8 Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study Unknown status NCT01737463 Phase 4
9 The Effect of Application of Fibrinogen/Thrombin-coated Collagen Patch (TachoSil®) in Pancreaticojejunostomy for Prevention of Pancreatic Fistula After Pancreatoduodenectomy Unknown status NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
10 Application of Pinaverium Bromide in the Treatment of Patients With Post-cholecystectomy Sphincter of Oddi Dysfunction (SOD): A Randomized, Controlled and Multicenter Clinical Study Unknown status NCT02833103 Phase 4 Danshu Capsules;Pinaverium Bromide
11 DOLCE Study: Day-care Versus Overnight-stay Laparoscopic Cholecystectomy Randomized, Controlled Trial Unknown status NCT01052727 Phase 4
12 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
13 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir(RAL)in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
14 Prospective Assessment of Valproate on Ethanol Withdrawal Unknown status NCT03235531 Phase 4 Valproate;Lorazepam
15 Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis Completed NCT00957151 Phase 4 Creon
16 Randomized Controlled Trial on Sterile Fluid Collections Management in Acute Pancreatitis Completed NCT00786929 Phase 4 Conservative treatment
17 Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis Completed NCT00318994 Phase 4 Meropenem
18 Imipenem Prophylaxis of Infectious Complications in Patients With Acute Pancreatitis Completed NCT02897206 Phase 4 Imipenem;Placebo
19 A Prospective Study of Celiac Block Technique: One Injection or Two? Completed NCT00583479 Phase 4
20 Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP) Completed NCT02111707 Phase 4 Rectal indomethacin 100mg one time before or after ERCP
21 Double-blind Randomized Study to Determine the Efficacy of Intramuscular Vitamin D3 Supplementation in Tropical Calcific Pancreatitis Completed NCT00956839 Phase 4 Vitamin D3 (Cholecalciferol)
22 Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube Completed NCT00999232 Phase 4 Erythromycin;Placebo
23 A Multicentre, Randomised, Double-blind, Placebo-controlled, Study on the Use of Prophylactic Meropenem Therapy in Subjects With Severe Acute Necrotizing Pancreatitis Completed NCT00061438 Phase 4 meropenem
24 A Prospective Randomised Trial of 0.025 Wire Guided Cannulation Versus Current Practice 0.035 Wire Guided Cannulation Completed NCT01408264 Phase 4
25 The Impact of Early Enteral Nutrition on the Clinical Outcomes of Severe Acute Pancreatitis Patients: A Randomized Control Trial Completed NCT00995098 Phase 4
26 Diclophenac Potassium Versus Ceftazidime for Reduction of Post ERCP Pancreatitis in Average Risk Patients-double Blind, Randomised Controlled Trial Completed NCT01784445 Phase 4 Ceftazidime
27 Enteral Nutrition for Treatment of Acute Pancreatitis - a Prospective, Randomized Clinical Trial Completed NCT01965873 Phase 4
28 APCAP - Activated Protein C in Severe Acute Pancreatitis: A Double-blind Randomized Human Pilot Trial Completed NCT01017107 Phase 4 Activated protein C
29 Dexmedetomidine vs Placebo in ERCP Sedation.A Randomized Pilot Study Completed NCT01070680 Phase 4 Precedex;sodium chlorid 0,9%
30 Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients Completed NCT00560157 Phase 4
31 A Double-Blind, Randomized, Placebo Controlled Intervention Study to Assess the Impact of Sitagliptin 100 mg/Day for 1 Year on Insulin Independence Following Pancreatectomy and Autoislet Transplantation Completed NCT01186562 Phase 4 Sitagliptin;Placebo
32 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Randomized Multi-center Study Completed NCT01744847 Phase 4
33 The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Completed NCT01507766 Phase 4 early enteral nutrition;Delayed enteral nutrition
34 Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen Completed NCT01430234 Phase 4 Panzytrat 25.000 FIP-E units of Lipase
35 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
36 Studie Naar De Effectiviteit Van Ursodeoxycholzuur Ter Preventie Van Galsteen-Gerelateerde Klachten Bij patiënten in Afwachting Van Een Cholecystectomie Completed NCT00161083 Phase 4 ursodeoxycholic acid
37 Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Atazanavir/Ritonavir + Lamivudine in Patients Stably Treated With Two NRTIs + Atazanavir/Ritonavir With Optimal Virologic Response. Completed NCT00885482 Phase 4 Lamiduvine (Epivir);Atazanavir (Reyataz);Ritonavir (Norvir)
38 A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease Completed NCT02703194 Phase 4 Prednisone;Leflunomide
39 Beijing Chao-Yang Hospital, Capital Medical University Completed NCT03297879 Phase 4 Exenatide or metformin hydrochloride
40 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
41 A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU Patients Completed NCT01734525 Phase 4 Anidulafungin
42 Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy: Prospective Multicenter Randomized Study Completed NCT01550406 Phase 4
43 A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Effect of 12-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Liraglutide or Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Sitagliptin on the Cardiovascular, Renal and Gastrointestinal System in Insulin-naïve Patients With Type 2 Diabetes (T2DM). Completed NCT01744236 Phase 4 Liraglutide;Sitagliptin;Exenatide;Liraglutide placebo;Sitagliptin placebo;Exenatide placebo;L-NMMA
44 Exploratory, Cross-sectional Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy Completed NCT01116817 Phase 4 Lumbar puncture (Lopinavir/ritonavir monotherapy);Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)
45 A Randomised, Double Blind Cross-over Study of Serial MRCP Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers Completed NCT01134848 Phase 4 Morphine;Neostigmine;0.9% saline;Secretin;0.9% saline
46 Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial: The EFFORT Trial Completed NCT02517476 Phase 4
47 Evaluation of Safety and Efficacy of Raltegravir/Darunavir Combination in Antiretroviral-Naive Patients Completed NCT00677300 Phase 4 Raltegravir;Darunavir;Ritonavir;Tenofovir/Emtricitabine
48 A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment: Randomized Trial Completed NCT03635372 Phase 4 Alginate;Sucralfate;Hydrotalcite
49 Randomised and Prospective Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens Completed NCT00994344 Phase 4 Darunavir/ritonavir;Lopinavir/ritonavir
50 To Study the Effects of Lipid Emulsion on Hemodynamics in Organophosphate Compound Poisoning Completed NCT03564574 Phase 4

Search NIH Clinical Center for Pancreatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Propantheline
Propantheline Bromide

Genetic Tests for Pancreatitis

Genetic tests related to Pancreatitis:

# Genetic test Affiliating Genes
1 Pancreatitis 29

Anatomical Context for Pancreatitis

MalaCards organs/tissues related to Pancreatitis:

40
Pancreas, Testes, Liver, Lung, Colon, Kidney, Neutrophil

Publications for Pancreatitis

Articles related to Pancreatitis:

(show top 50) (show all 30199)
# Title Authors PMID Year
1
The natural history of hereditary pancreatitis: a national series. 61 54 24
18755888 2009
2
Association of rare chymotrypsinogen C (CTRC) gene variations in patients with idiopathic chronic pancreatitis. 61 54 24
18172691 2008
3
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. 24 61 54
18059268 2008
4
Diabetes mellitus in Tropical Chronic Pancreatitis Is Not Just a Secondary Type of Diabetes. 24 54 61
15258409 2004
5
SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. 61 54 24
10982753 2000
6
Prevention of Severe Acute Pancreatitis With Cyclooxygenase-2 Inhibitors: A Randomized Controlled Clinical Trial. 61 42
32142484 2020
7
Discussion on: The morbidity of C. difficile in necrotizing pancreatitis. 42 61
32199538 2020
8
Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest. 61 24
24555976 2014
9
Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. 24 61
24152948 2013
10
Variants in CPA1 are strongly associated with early onset chronic pancreatitis. 24 61
23955596 2013
11
Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. 61 24
23890130 2013
12
CFTR, SPINK1, CTRC and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated? 24 61
22427236 2013
13
Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. 24 61
23100216 2013
14
Endoscopic therapy is effective for patients with chronic pancreatitis. 61 24
22245964 2012
15
Whole exome sequencing identifies multiple, complex etiologies in an idiopathic hereditary pancreatitis kindred. 61 24
22572128 2012
16
Genetics of pancreatitis: an update for clinicians and genetic counselors. 24 61
22314809 2012
17
Drug-induced pancreatitis. 61 24
22314811 2012
18
Oxidative stress in chronic pancreatitis: pathophysiological relevance and management. 61 24
21902596 2011
19
Genetics of pancreatitis. 24 61
21844754 2011
20
Quality of life improves for pediatric patients after total pancreatectomy and islet autotransplant for chronic pancreatitis. 61 24
21683160 2011
21
Imaging of acute pancreatitis. 24 61
21785045 2011
22
High incidence of PRSS1 and SPINK1 mutations in Korean children with acute recurrent and chronic pancreatitis. 24 61
21415673 2011
23
Correlation of histopathology, islet yield, and islet graft function after islet autotransplantation in chronic pancreatitis. 61 24
21404456 2011
24
Use and perceived effectiveness of non-analgesic medical therapies for chronic pancreatitis in the United States. 61 24
21083584 2011
25
Therapeutic implications of oxidative stress in acute and chronic pancreatitis. 24 61
20543682 2010
26
The role of alcohol and smoking in pancreatitis. 61 24
20125091 2010
27
Outcomes of interventional ERCP in hereditary pancreatitis. 61 24
19713862 2010
28
Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. 61 24
19506173 2009
29
Assessment of chronic pancreatitis: utility of diffusion-weighted MR imaging with secretin enhancement. 24 61
19001148 2009
30
A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis. 61 24
18952082 2009
31
Hereditary pancreatitis caused by a double gain-of-function trypsinogen mutation. 61 24
18461367 2008
32
Copy number variations in chronic pancreatitis. 61 24
19287144 2008
33
Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. 24 61
18184119 2008
34
Trypsinogen copy number mutations in patients with idiopathic chronic pancreatitis. 24 61
18063422 2008
35
Hereditary pancreatitis amlodipine trial: a pilot study of a calcium-channel blocker in hereditary pancreatitis. 61 24
18090235 2007
36
Genetic counseling for nonsyndromic pancreatitis. 61 24
17533082 2007
37
Pain in chronic pancreatitis and pancreatic cancer. 61 24
17533083 2007
38
13C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. 61 24
17445754 2007
39
Yoga: a tool for improving the quality of life in chronic pancreatitis. 24 61
17230607 2007
40
Practice guidelines in acute pancreatitis. 61 24
17032204 2006
41
Cigarette smoking accelerates progression of alcoholic chronic pancreatitis. 24 61
15753536 2005
42
Genetic counseling for hereditary pancreatitis--the role of molecular genetics testing for the cationic trypsinogen gene, cystic fibrosis and serine protease inhibitor Kazal type 1. 54 24
15528021 2004
43
Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. 24 61
11448279 2001
44
Chronic pancreatitis: diagnosis, classification, and new genetic developments. 24 61
11179244 2001
45
Pancreatitis induced by environmental toxins. 24 61
11138962 2001
46
Antioxidant treatment in hereditary pancreatitis. A pilot study on three young patients. 24 61
11303976 2001
47
Genetic testing for hereditary pancreatitis: guidelines for indications, counselling, consent and privacy issues. 61 24
12120217 2001
48
Pancreatic cancer in hereditary pancreatitis: consensus guidelines for prevention, screening and treatment. 24 61
12120218 2001
49
Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study. 61 24
10859041 2000
50
Hereditary pancreatitis: new insights, new directions. 61 24
11030605 1999

Variations for Pancreatitis

ClinVar genetic disease variations for Pancreatitis:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TMEM67 NM_153704.6(TMEM67):c.1843T>C (p.Cys615Arg)SNV Pathogenic/Likely pathogenic 1383 rs201893408 8:94808198-94808198 8:93795970-93795970
2 TMEM67 NM_153704.6(TMEM67):c.1321C>T (p.Arg441Cys)SNV Pathogenic/Likely pathogenic 217725 rs752362727 8:94798483-94798483 8:93786255-93786255
3 CFTR NM_000492.4(CFTR):c.1523T>G (p.Phe508Cys)SNV Conflicting interpretations of pathogenicity 7126 rs74571530 7:117199648-117199648 7:117559594-117559594
4 CFTR NM_000492.4(CFTR):c.2991G>C (p.Leu997Phe)SNV Conflicting interpretations of pathogenicity 7229 rs1800111 7:117250575-117250575 7:117610521-117610521
5 CFTR NM_000492.4(CFTR):c.1584G>A (p.Glu528=)SNV Conflicting interpretations of pathogenicity 43576 rs1800095 7:117199709-117199709 7:117559655-117559655

Copy number variations for Pancreatitis from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 194974 5 147184338 147191453 Deletion SPINK1 Pancreatitis
2 220321 7 137300000 142800000 Triplication PRSS1 Pancreatitis
3 220322 7 137300000 142800000 Triplication PRSS2 Pancreatitis
4 221070 7 142136892 142140501 Triplication PRSS1 Pancreatitis
5 221298 7 142800000 147500000 Triplication PRSS1 Pancreatitis

Expression for Pancreatitis

Search GEO for disease gene expression data for Pancreatitis.

GO Terms for Pancreatitis

Cellular components related to Pancreatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 SST SPINK1 SCT REG3A REG1B REG1A
2 extracellular space GO:0005615 9.5 SST SPINK1 SCT REG3A REG1B REG1A
3 very-low-density lipoprotein particle GO:0034361 9.26 LPL APOC2
4 chylomicron GO:0042627 9.16 LPL APOC2

Biological processes related to Pancreatitis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.91 PRSS2 PRSS1 CTRC CPB1 CPA1
2 positive regulation of cell proliferation GO:0008284 9.88 REG3A REG1B REG1A CCK CASR
3 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.58 REG3A REG1B REG1A
4 sperm capacitation GO:0048240 9.54 SPINK1 CFTR
5 retinoid metabolic process GO:0001523 9.54 PNLIP LPL APOC2
6 cobalamin metabolic process GO:0009235 9.52 PRSS1 CTRC
7 response to peptide hormone GO:0043434 9.5 REG3A REG1B REG1A
8 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.49 PLA2G2A LPL
9 very-low-density lipoprotein particle remodeling GO:0034372 9.46 LPL APOC2
10 lipid catabolic process GO:0016042 9.46 PNLIP PLA2G2A LPL APOC2
11 chylomicron remodeling GO:0034371 9.43 LPL APOC2
12 antimicrobial humoral response GO:0019730 9.43 REG3A PRSS2 PLA2G2A
13 digestion GO:0007586 9.26 SST PRSS2 PRSS1 CCK
14 cell wall disruption in other organism GO:0044278 8.8 REG3A REG1B REG1A

Molecular functions related to Pancreatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.76 PRSS2 PRSS1 PNLIP PLA2G2A LPL CTRC
2 peptidase activity GO:0008233 9.72 PRSS2 PRSS1 CTRC CPB1 CPA1
3 signaling receptor activity GO:0038023 9.56 REG3A REG1B REG1A CASR
4 hormone activity GO:0005179 9.54 SST SCT CCK
5 triglyceride lipase activity GO:0004806 9.43 PNLIP LPL
6 lipase activity GO:0016298 9.4 PNLIP LPL
7 peptidoglycan binding GO:0042834 9.13 REG3A REG1B REG1A
8 oligosaccharide binding GO:0070492 8.8 REG3A REG1B REG1A

Sources for Pancreatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....